Top Markets
#1 Akedo Akedo +84.18%
#2 TENDIES TENDIES +73.28%
#3 Verus Coin Verus Coin +43.84%
#4 Threshold Network Threshold Network +42.58%
#5 Mubarak Mubarak +31.80%
#6 MultiversX MultiversX +27.43%
#7 Bitway Bitway +26.80%
#8 Cash Cat Cash Cat +24.01%
#9 Palladium Network Palladium Network +22.68%
#10 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
Coin of the day
Akedo Akedo
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Classement en actions #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Prix de l'action
$8.16
Dernière synchronisation: 2025-06-26
Capitalisation boursière
$234.57M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Regulus Therapeutics Inc. (RGLS)

Catégorie

Healthcare
Bénéfices pour Regulus Therapeutics Inc. (RGLS)
Bénéfices en Mar 2025 TTM : $-47.52M
Selon les derniers rapports financiers de Regulus Therapeutics Inc., les bénéfices actuels de l'entreprise sont de $-47.52M. En 2023, l'entreprise a réalisé un bénéfice de $-30.04M, une diminution par rapport à celui de 2022 qui était de $-28.32M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Regulus Therapeutics Inc. de 2010 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $-47.52M 2.51%
2024 $-46.36M 54.34%
2023 $-30.04M 6.05%
2022 $-28.32M 1.85%
2021 $-27.81M 76.78%
2020 $-15.73M -15.39%
2019 $-18.59M -61.78%
2018 $-48.65M -32.53%
2017 $-72.10M -11.90%
2016 $-81.84M 46.76%
2015 $-55.77M -1.61%
2014 $-56.68M 203.24%
2013 $-18.69M 7.31%
2012 $-17.42M 135.51%
2011 $-7.40M -52.56%
2010 $-15.59M 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -11,199.91%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -4,204.73%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 6,395.94%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 8,351.24%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH